497. Safety and tolerability of 2000mg intravenous sotrovimab dose in immunocompromised participants uninfected with SARS-CoV-2 in the PROTECT-V trial

BACKGROUND: There remains a need for pre-exposure prophylaxis against SARS-CoV-2 infection in vulnerable patients in whom response to vaccination is often sub-optimal. The PROTECT-V platform trial is testing pre-exposure prophylactic interventions for COVID-19 in vulnerable patient populations: tran...

Descripción completa

Detalles Bibliográficos
Autores principales: Dosanjh, Davinder, Qian, Wendi, Dowling, Francis, Crowley, Louise, Chen-Xu, Michael, Smith, Rona M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679160/
http://dx.doi.org/10.1093/ofid/ofad500.566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679160/
http://dx.doi.org/10.1093/ofid/ofad500.566

Ejemplares similares